Pharma Mar SA (PHM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Pharma Mar SA (PHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9808
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar’s developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA (PHM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13
Merger 14
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14
Licensing Agreements 15
Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16
Pharma Mar Enters into Licensing Agreement with Megapharm 17
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19
Eczacibasi Enters into Licensing Agreement with Pharma Mar 20
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24
TTY Biopharm Enters into Licensing Agreement with PharmaMar 25
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27
Equity Offering 28
Pharma Mar Plans to Raise Funds through Public Offering of ADS 28
Pharma Mar SA – Key Competitors 29
Pharma Mar SA – Key Employees 30
Pharma Mar SA – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Financial Announcements 33
Oct 30, 2018: PharmaMar reports net profit of €5 million at the end of the third quarter of 2018 33
Jul 26, 2018: PharmaMar group obtained a net profit of €3 million in the first half of 2018 34
Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results 35
Feb 28, 2018: PharmaMar group announces 2017 earnings results 36
Oct 24, 2017: Pharma Mar group revenues totalled €140 million in the first nine months of the year 37
Jul 26, 2017: Pharma Mar group reports first half financial results 38
Apr 27, 2017: PharmaMar Group reports €45.5 million in revenues (+8%) 39
Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 40
Corporate Communications 42
Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development 42
Government and Public Interest 43
Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 43
Product News 45
06/16/2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 45
04/27/2017: PharmaMar demonstrates its progress in R&D in New York 46
04/04/2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 47
Clinical Trials 48
Sep 19, 2017: PharmaMar Starts Clinical Studies with a New Compound –PM14- in Patients with Solid Tumors 48
Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 49
May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 50
Other Significant Developments 51
Jul 30, 2018: Immedica – a platform for pan-European niche specialty pharma launch, commercialization and distribution services 51
Jun 28, 2018: PharmaMar’s 2017 Group Annual General Shareholder’s’ meeting 52
Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14
Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16
Pharma Mar Enters into Licensing Agreement with Megapharm 17
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19
Eczacibasi Enters into Licensing Agreement with Pharma Mar 20
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24
TTY Biopharm Enters into Licensing Agreement with PharmaMar 25
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27
Pharma Mar Plans to Raise Funds through Public Offering of ADS 28
Pharma Mar SA, Key Competitors 29
Pharma Mar SA, Key Employees 30
Pharma Mar SA, Subsidiaries 31

List of Figures
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Pharma Mar SA (PHM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Casio Computer Co., Ltd.:企業の戦略・SWOT・財務分析
    Casio Computer Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Casio Computer Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Dai Nippon Printing Co., Ltd.:企業の戦略・SWOT・財務分析
    Dai Nippon Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dai Nippon Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • EP Global Energy Ltd:電力:M&Aディール及び事業提携情報
    Summary EP Global Energy Ltd (EPGE) a subsidiary of Joannou & Paraskevaides (Overseas) Ltd. is a renewable energy service provider that offers services for development of wind, hybrid, solar power energy and conventional energy projects. The company offers renewable energy development, design, civil …
  • Equinor ASA (EQNR):企業の財務・戦略的SWOT分析
    Equinor ASA (EQNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Falck Renewables S.p.A. (FKR):電力:M&Aディール及び事業提携情報
    Summary Falck Renewables S.p.A. (Falck Renewables), formerly Actelios S.p.A that develops, designs, constructs and manages energy production plants. It operates as a subsidiary of Falck S.p.A. The company produces clean energy from various renewable sources including wind energy, solar energy, bioma …
  • Flex Ltd.:企業の戦略・SWOT・財務分析
    Flex Ltd. - Strategy, SWOT and Corporate Finance Report Summary Flex Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • SMS Pharmaceuticals Ltd (SMSPHARMA):製薬・医療:M&Aディール及び事業提携情報
    Summary SMS Pharmaceuticals Ltd (SMS Pharma) is a manufacturer of active pharmaceutical ingredients (APIs) and intermediates that develops offers anti-fungal, anti-ulcer, anti-migraine, anti-hypersensitive, anti-psychotic, anti-viral and other products. Its pipeline products include Ticagrelor, Clop …
  • Pulse Seismic Inc (PSD):企業の財務・戦略的SWOT分析
    Summary Pulse Seismic Inc (Pulse), formerly Pulse Data Inc is a provider of seismic data library for oil and gas exploration. The company acquires, markets and licenses 2D and 3D seismic data to the western Canadian energy sector. It offers services such as project cost tracking, scouting, geophysic …
  • 908 Devices Inc:医療機器:M&Aディール及び事業提携情報
    Summary 908 Devices Inc (908 Devices) is a manufacturer of handheld chemical detection tools, tiny footprint analyzers and fast separation devices. The company’s product portfolio includes MX908, a second-generation tool that leverages high-pressure mass spectrometry (HPMS); M908 focuses on priority …
  • Swan Life Ltd.:企業の戦略・SWOT・財務情報
    Swan Life Ltd. - Strategy, SWOT and Corporate Finance Report Summary Swan Life Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Tokyo Seimitsu Co., Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Seimitsu Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Seimitsu Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Crescent Point Energy Corp (CPG):企業の財務・戦略的SWOT分析
    Crescent Point Energy Corp (CPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Neftisa:石油・ガス:M&Aディール及び事業提携情報
    Summary Neftisa is an upstream oil and gas company. The company's activities include prospecting and development of hydrocarbon reservoirs, oil production, gas condensate recovery, conversion of oil associated gas, oil-and-gas fields development and extraction, maintenance and monitoring of oil serv …
  • Svenska Cellulosa Aktiebolaget:企業の戦略・SWOT・財務情報
    Svenska Cellulosa Aktiebolaget - Strategy, SWOT and Corporate Finance Report Summary Svenska Cellulosa Aktiebolaget - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Jadranski naftovod dd (JNAF-R-A):企業の財務・戦略的SWOT分析
    Summary Jadranski naftovod dd (JANAF Plc) is an oil pipeline system managing company that operates crude oil transportation system and reloading and storage of crude oil and oil products. The company manages janaf system, an international crude oil transportation system. Its janaf systems consists o …
  • Polenergia SA (PEP):企業の財務・戦略的SWOT分析
    Polenergia SA (PEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Aesculap Inc:企業の製品パイプライン分析2018
    Summary Aesculap Inc (Aesculap) is a medical device company that offers medical implants, surgical implants, and other related devices. The company’s products comprise neurosurgery products, power systems, sterile processing products, surgical instruments, and wound closure products. It offers servi …
  • Carl Zeiss Meditec AG (AFX):製品パイプライン分析
    Summary Carl Zeiss Meditec AG (Carl Zeiss Meditec), a division of Carl Zeiss AG, an integrated medical technology company which operates in the fields of ophthalmology, neuro/ENT surgery and surgical ophthalmology. It provides comprehensive packages of solutions for the diagnosis and treatment of ey …
  • Barclays Bank of Kenya Ltd:企業の戦略・SWOT・財務分析
    Barclays Bank of Kenya Ltd - Strategy, SWOT and Corporate Finance Report Summary Barclays Bank of Kenya Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Obalon Therapeutics Inc (OBLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Obalon Therapeutics Inc (Obalon Therapeutics) is a manufacturer of medical devices and equipment. The company offers development and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It also researches, designs, produces, and sells medical gast …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆